ArticleJournal of family medicine and primary care2026
Efficacy, safety, and tolerability of ubrogepant in the treatment of acute migraine among migraine patients in Hail City, Saudi Arabia: A retrospective case.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraines represent a significant health burden globally and are particularly prevalent in Saudi Arabia, with rates exceeding the global average. Effective management of acute migraine attacks is crucial for improving patient outcomes. Ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, has shown promise in treating acute migraines. While previous research has confirmed its efficacy and safety in different populations, there is a lack of localized data evaluating its use among patients in Saudi Arabia. To evaluate the efficacy, safety, and tolerability of Ubrogepant 100 mg for acute migraine management among patients in Hail City, Saudi Arabia. This retrospective case series included all patients prescribed Ubrogepant 100 mg for acute migraine attacks. Eligible patients were identified through electronic medical records and contacted via patient portal, phone, or clinic visits to complete a 15-item open-ended questionnaire. The survey assessed treatment response, safety, and tolerability of Ubrogepant. Among 27 migraine patients treated with Ubrogepant, nearly 70% achieved complete headache resolution within 2 hours, and 80% experienced significant migraine relief within 1.5 hours. Functional disability scores significantly improved (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.